Mary F. Mulcahy, MD, describes the treatment options available for colorectal cancer with liver metastasis in the first and second line.
Mary F. Mulcahy, MD: Hello, I’m Mary Mulcahy from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
Liver metastasis is the most common site of metastases for colorectal cancer. Standard treatment involves systemic chemotherapy with multidrug agents and often biologic agents in addition, either a VEGF [vascular endothelial growth factor] or an EGFR [epidermal growth factor receptor] inhibitor. In a small number of cases, immunotherapy may be beneficial. For liver-only disease, we try to incorporate liver resection when possible. However, of all patients with metastatic disease to the liver, about 80% aren’t amenable to any surgical intervention or local ablative therapy intervention. For those, we’re seeking out other treatments to enhance the effects of the chemotherapy on liver-only metastasis. Right now, the standard of care therapy is multiagent systemic chemotherapy with a biologic agent. When there’s disease confined to a small area, to a lobe, or perhaps multilobar disease, some of it may be amenable to surgical resection or ablative therapy. However, the majority of these cases aren’t.
Patients who have liver-only disease may have disease isolated to 1 section of the liver, or they may have diffuse metastatic disease. Patients with diffuse metastatic disease throughout multiple lobes of the liver often don’t have a local ablative option. For those who have disease isolated to or perhaps predominant in 1 lobe of the liver and minimal disease in the other lobe, with lots of intervention and a good response to therapy, we may be able to clear the liver of all disease. That might require using things like hepatic artery infusion or ablative techniques. There are a number of different techniques that have been used in the liver to try to clear it of all disease. However, for those cases that are multifocal in multiple lobes—bilobar, multifocal disease—oftentimes, liver-directed therapies with ablation or surgery won’t clear all disease. It will leave disease behind.
Transcript edited for clarity.
Retrospective Data Demonstrates Efficacy of Regorafenib in mCRC
April 16th 2024During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Read More
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Study Finds Susceptibility Gene Variations by Race/Ethnicity in Early-Onset CRC
February 20th 2024In an interview with Targeted Oncology, Andreana N. Holowatyj, PhD, MSCI, discussed data from a study which found racial and ethnic differences in susceptibility genes for early-onset colorectal cancer, suggesting current multigene panel tests may not be accurate for diverse populations.
Read More